Navigation Links
Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
Date:11/23/2007

PRINCETON, N.J., and PARIS, Nov. 23 /PRNewswire-FirstCall/ -- Bristol- Myers Squibb Company (NYSE: BMY) and Pierre Fabre Medicament reported today that they are terminating their license agreement for the development of vinflunine, a chemotherapy agent under investigation for the treatment of advanced or metastatic bladder cancer and other tumor types. Vinflunine was developed by Pierre Fabre Medicament and licensed to Bristol-Myers Squibb in 2004 for specific territories. Based on a review of the clinical development program and the decision not to file a new drug application for bladder cancer in the United States, coupled with an analysis of Bristol-Myers Squibb's Research & Development priorities, the companies have jointly decided that all rights licensed to Bristol-Myers Squibb for vinflunine will be returned to Pierre Fabre Medicament.

"In Europe, Pierre Fabre Medicament intend to continue discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008," said P. Hurteloup, General Manager of Pierre Fabre Medicament Oncology Division. "We also are considering a range of further development options, including pursuing the product on a worldwide basis for the treatment of a number of cancers."

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Pierre Fabre Medicament is a French private group dedicated to consumers and patients from health to beauty.


'/>"/>
SOURCE Bristol-Myers Squibb Company; Pierre Fabre Medicament
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
5. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
6. CardioDynamics Provides 2007 Shareholder Meeting Update
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
9. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
10. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
11. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... Basel, Switzerland (PRWEB) , ... July 18, 2017 ... ... for R&D, today announced that Merck, a leading science and technology company, has ... develop innovative therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope ... released the first phase of the Allotrope Framework for commercial use. , The ... created to “not only elevate the critical role of information technology in modern ...
(Date:7/17/2017)... ... July 17, 2017 , ... The Academy of Model ... of National Model Aviation Day will take place from 9 a.m. to 2 p.m. ... include activities for all ages. , Aviation Adventure Day will be packed with entertaining ...
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders (NDDs) ... of overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) has been ... and testing. , However, designing a custom panel for disease research requires ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):